Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 134

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 4
Chunk 134
---
ists of nineteen utility patent families, including patents and applications having method of use and composition of matter claims.
Fourteen of the patent families are solely owned by the Company, one is jointly owned with BIRAD, the R& D company of Bar-Ilan University
and two are jointly owned with Yissum, the Research Development Company of the Hebrew University of Jerusalem. In addition, we have licensed
two patents from Yissum Research Development Company of the Hebrew University of Jerusalem. The nineteen patent families include thirty
granted patents and fifty three pending applications:

  Alcoholic Beverage Substitute: 9 patents, 6 pending applications. The 20 year term for the “ Alcoholic Beverage Substitutes” family ends on December 9, 2035.  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  Binge Behavior Regulators: 21 patents, 4 pending applications. The “ Binge Behavior Regulators” family has a 20-year term that ends December, 9, 2035.  
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  Benzofurans as Fail Safes for MDMA Therapy: 5 pending applications. The 20 year term for this family ends on October 6, 2042.  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  2-FDCK for Treatment of Depression, Including Treatment-Resistant Depression: 7 pending applications. The 20 year term for this family ends on October 18, 2042.  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  Compositions comprising MEAI and n-acylethanolamines and uses thereof: 10 pending applications. The 20 year term for this family ends on March 6, 2043.  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  MEAI for the treatment of Cocaine Addiction: 7 pending applications. The 20 year term for this family ends on May 31, 2043.  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  MEAI for the treatment of Metabolic Syndrome: 1 pending application. The 20 year term for this family ends